Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections (IGNITE3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03032510
Recruitment Status : Completed
First Posted : January 26, 2017
Results First Posted : October 2, 2019
Last Update Posted : October 2, 2019
Sponsor:
Information provided by (Responsible Party):
Tetraphase Pharmaceuticals, Inc.

Tracking Information
First Submitted Date  ICMJE January 17, 2017
First Posted Date  ICMJE January 26, 2017
Results First Submitted Date  ICMJE July 12, 2019
Results First Posted Date  ICMJE October 2, 2019
Last Update Posted Date October 2, 2019
Actual Study Start Date  ICMJE January 2017
Actual Primary Completion Date December 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 9, 2019)
  • Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the EOI Visit [ Time Frame: End of Infusion ]
    This was the co-primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to ertapenem in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to <10^4 colony-forming units/milliliter (CFU/mL). An outcome of Responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.
  • Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) Visit [ Time Frame: TOC visit (14-17 days after randomization) ]
    This was the co-primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to ertapenem in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to <10^4 colony-forming units/milliliter (CFU/mL). An outcome of responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.
Original Primary Outcome Measures  ICMJE
 (submitted: January 23, 2017)
  • Proportion of Participants in the microbiological Intent-to-treat (micro-ITT) Population Demonstrating Clinical Cure and Microbiologic Success at the End of Intravenous (EOI) Visit [ Time Frame: EOI visit (within 1 day of the completion of intravenous study drug treatment) ]
  • Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) Visit [ Time Frame: TOC visit (14-17 days after randomization) ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 9, 2019)
Proportion of Participants in the ITT Population With Favorable Clinical Outcomes at TOC Visit [ Time Frame: TOC visit (14-17 days after randomization) ]
Clinical cure: A complete resolution or significant improvement of signs or symptoms of the infection such that no rescue/non-study antibacterial medication was required to treat the cUTI that presented at study entry. Clinical failure: Subjects were classified as clinical failure in the event of
  • Death related to cUTI at any timepoint
  • Persistence of clinical symptoms of cUTI or new symptoms developed
  • Initiation of rescue/non-study antibacterial medication for cUTI Indeterminate: Study data were listed as indeterminate if the outcome was other than clinical cure or clinical failure. The reason for an indeterminate designation had to be provided Missing: Study data were listed as missing if the Investigator did not complete an assessment or if the subject did not complete the study visit.
Original Secondary Outcome Measures  ICMJE
 (submitted: January 23, 2017)
Proportion of Participants in the microbiological Modified Intent-To-Treat (micro-MITT) Population and the Microbiologically Evaluable (ME) Population Demonstrating Microbiologic Success at the TOC Visit [ Time Frame: TOC visit (14-17 days after randomization) ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
Official Title  ICMJE A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Brief Summary The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).
Detailed Description

The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).

This is a phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety and pharmacokinetics of eravacycline compared with ertapenem in the treatment of cUTI.

Randomization will be stratified based on two criteria: (1) by primary site of infection (pyelonephritis and normal urinary tract anatomy vs all other diagnoses) and (2) by the receipt of a single dose of effective non-study antibiotics for the acute cUTI within 72 hours prior to randomization. An enrollment cap of approximately 50% is planned for subjects with pyelonephritis with normal urinary tract anatomy. Also, an enrollment cap of approximately 20% is planned for subjects who have received a single dose of non-study antibiotics for the acute cUTI within 72 hours prior to randomization.

In this study subjects will be enrolled and randomized to one of two treatment arms in a 1:1 ratio: (i) eravacycline intravenously (IV) / levofloxacin (PO), or (ii) ertapenem (IV) / levofloxacin (PO).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Complicated Urinary Tract Infections
Intervention  ICMJE
  • Drug: Eravacycline
    Other Name: TP-434
  • Drug: Ertapenem
    Other Name: Invanz
  • Drug: Placebo
  • Drug: Levofloxacin
    Other Name: Levaquin
Study Arms  ICMJE
  • Experimental: Eravacycline (Intravenous)/Levofloxacin (Oral)
    Interventions:
    • Drug: Eravacycline
    • Drug: Placebo
    • Drug: Levofloxacin
  • Active Comparator: Ertapenem (Intravenous)/Levofloxacin (Oral)
    Interventions:
    • Drug: Ertapenem
    • Drug: Placebo
    • Drug: Levofloxacin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 9, 2019)
1205
Original Estimated Enrollment  ICMJE
 (submitted: January 23, 2017)
1200
Actual Study Completion Date  ICMJE January 2018
Actual Primary Completion Date December 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male or female participant with either:

    1. Pyelonephritis and normal urinary tract anatomy (approximately 50% of the total population), or
    2. cUTI with at least one of the following conditions associated with a risk for developing cUTI:

      • Indwelling urinary catheter
      • Urinary retention (at least approximately 100 milliliters (mL) of residual urine after voiding)
      • History of neurogenic bladder
      • Partial obstructive uropathy (for example, nephrolithiasis, bladder stones, and ureteral strictures)
      • Azotemia of renal origin (not congestive heart failure [CHF] or volume related) such that the serum blood urea nitrogen [BUN] is elevated (>20 milligrams [mg]/deciliters [dL]) and the serum BUN:creatinine ratio is <15
      • Surgically modified or abnormal urinary tract anatomy (for example, bladder diverticula, redundant urine collection system) except urinary tract surgery within the last 30 days (placing of stents or catheters is not considered to be surgical modification)
  2. At least 18 years of age at time of consent
  3. Able to provide informed consent
  4. At least two of the following signs or symptoms:

    1. Chills, rigors, or warmth associated with fever or hypothermia
    2. Flank pain (pyelonephritis) or pelvic pain (cUTI)
    3. Nausea or vomiting
    4. Dysuria, urinary frequency, or urinary urgency
    5. Costo-vertebral angle tenderness on physical examination
  5. Urine specimen with evidence of pyuria

    1. Dipstick analysis positive for leukocyte esterase (where positive result is at least "++" as indicated on the urine dipstick provided in the laboratory kit), or
    2. ≥10 white blood cells (WBCs) per cubic millimeter, or
    3. ≥10 WBCs per high power field
  6. If male: must agree to use an effective barrier method of contraception (for example, condom) during the study and for 14 days following the last dose if sexually active with a female of childbearing potential
  7. If female, not pregnant or nursing or, if of childbearing potential: must commit to either use at least two medically accepted, effective methods of birth control (for example, condom, spermicidal gel, oral contraceptive, indwelling intrauterine device, hormonal implant /patch, injections, approved cervical ring) during study drug dosing and for 14 days following last study drug dose or practicing sexual abstinence

Exclusion Criteria:

  1. Use of systemic antibiotics effective in cUTI within 72 hours prior to enrollment except under the following circumstances:

    1. Participants with suspected acute cUTI who have received a single dose of effective non-study antibiotics for the acute cUTI
    2. Signs and symptoms of cUTI developed while on the antibiotic for another indication
  2. History of an ertapenem-resistant urinary tract infection within 1 year of enrollment
  3. Likely to require >10 days of antibiotic treatment to cure the acute cUTI or likely to receive ongoing antibacterial drug prophylaxis prior to the Follow Up visit (21-28 days after randomization) [for example, participants with chronic vesiculo-ureteral reflux]
  4. Unlikely to survive at least through the duration of the study
  5. Hypotension, systolic blood pressure ≤90 millimeters of mercury [mmHg]
  6. Complicated pyelonephritis with complete obstruction or known or suspected renal or perinephric abscess, emphysematous pyelonephritis, or Any condition likely to require surgery to achieve cure (this does not include procedure to place catheters or obtain diagnosis)
  7. Known or suspected urinary fungal infection
  8. Uncomplicated lower urinary tract infections
  9. Suspected or confirmed active prostatitis, or currently under treatment for prostatitis
  10. High risk for cUTI due to Pseudomonas (for example, history of prior cUTIs due to Pseudomonas, ≥20 mg once a day prednisone or equivalent steroid, and other risk factors as perceived by the Investigator)
  11. History of renal transplantation
  12. Presence of an ileal loop
  13. Any history of trauma to the pelvis or urinary tract occurring within 30 days of screening
  14. Indwelling urinary catheters present at screening which are not expected to be removed or replaced within 72 hours of enrollment (for example, nephrostomy tubes, stents, urethral and suprapubic catheters).
  15. Known concomitant human immunodeficiency virus (HIV) infection with CD4 counts below 200 within the last six months, or an acquired immune deficiency syndrome (AIDS) defining diagnosis within the last six months
  16. Neutropenia (Absolute neutrophil count <1,000 polymorphonuclear leukocytes [PMNs]/microliters [µL])
  17. Participation in a study with an experimental drug or device within 30 days prior to enrollment
  18. Known or suspected hypersensitivity to tetracyclines, carbapenems, or β-lactams
  19. History of seizures
  20. Any other unstable or clinically significant concurrent medical condition (for example, immunosuppressive therapy, chemotherapy, class IV heart or lung disease, end stage renal disease, or requiring hemodialysis) that would, in the opinion of the Investigator, jeopardize the safety of a participant and/or their compliance with the protocol
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   Bulgaria,   Estonia,   Georgia,   Hungary,   Latvia,   Moldova, Republic of,   Romania,   Russian Federation,   Slovakia,   Ukraine,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03032510
Other Study ID Numbers  ICMJE TP-434-021
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Tetraphase Pharmaceuticals, Inc.
Study Sponsor  ICMJE Tetraphase Pharmaceuticals, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Chief Medical Officer Tetraphase Pharmaceuticals
PRS Account Tetraphase Pharmaceuticals, Inc.
Verification Date September 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP